Effect of onconase on double-stranded RNA in vitro

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1067-1072

  Saxena, Abha ^a   Saxena, Shailendra K ^a   Shogen, Kuslima ^a  

^a Alfacell Corporation   (United States)

Author keywords

Cytotoxic; Double stranded RNA; Onconase; Ribonuclease; RNAi

Indexed keywords

DOUBLE STRANDED RNA; MICRORNA; RANPIRNASE; RIBONUCLEASE; SMALL INTERFERING RNA; TRANSFER RNA;

APOPTOSIS; ARTICLE; CELL DEATH; CYTOTOXICITY; ENZYME ACTIVITY; IN VITRO STUDY; INCUBATION TIME; PHENOTYPE; PRIORITY JOURNAL; RNA DEGRADATION; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELLS, CULTURED; ENDORIBONUCLEASES; GENE SILENCING; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; LYMPHOCYTES; MICRORNAS; RIBONUCLEASES; RNA, DOUBLE-STRANDED; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 64949132552     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Ardelt W, Mikulski SM and Shogen K: Amino acid sequence of antitumor protein from Rana-pipiens oocytes and early embryos. Homology to pancreatic ribonuclease. J Biol Chem 266: 245-251, 1991.
2. Ardelt W, Lee HS, Randolph G, Viera A, Mikulski SM and Shogen K: Enzymatic characterization of onconase, a novel ribonuclease with anti-tumor activity. Protein Sci 3(Supp 1): 137-147, 1994.
3. Mosiman SC, Ardelt W and James MNG: Refined 1.7A° X-ray crystallographic structure of P-30 protein, an amphibian ribonuclease with antitumor activity. Mol Biol 236: 41-53, 1994.
4. Pavlakis N and Vogelzang NJ: Ranpirnase-an antitumor ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther 6: 1391-1399, 2006.
5. Mikulski SM, Constanzi JJ and Vogelzang NJ: Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 20: 274-281, 2002.
6. Saxena SK, Gravell M, Wu YN, Mikulski SM, Shogen K, Ardelt W and Youle RJ: Inhibition of HIV-1 production and selective degradation of viral RNA by an amphibian ribonuclease. J Biol Chem 271: 20783-20788, 1996.
7. Saxena SK, Shogen K and Ardelt W: ONCONASE and its therapeutic potential. Lab Med 3: 380-387, 2003.
8. Wu Y, Mikulski SM, Ardelt W, Rybak SM and Youle RJ: A cytotoxic ribonuclease: Study of the mechanism of onconase cytotoxicity. J Biol Chem 268: 10686-10693, 1993.
9. Saxena SK, Sirdeshmukh R, Ardelt W, Mikulski SM, Shogen K and Youle RJ: Entry into cells and selective degradation of tRNA by a cytotoxic member of the RNase A family. J Biol Chem 277: 15142-15146, 2002.
10. Suhasini AN and Sirdeshmukh R: Transfer RNA cleavages by onconase reveal unusual cleavage sites. J Biol Chem 281: 12201-12209, 2006.
11. Lys3, the primer for HIV-1 reverse transcription. Biochem Biophys Res Comm 363: 304-309, 2007.
12. Mikulski S, Bersnstein E, Ardelt W, Shogen K and Menduke K: Striking increase in survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos. JNCI 82: 151-153, 1990.
13. Mikulski S, Viera A and Shogen K: In vitro synergism between a novel ambhibian oocytic ribonuclease (ONCONASE) and tamoxifen, lovastatin and cisplatin in human OVCAR-3 ovarian carcinoma cell line. Int J Oncol 1: 779-785, 1992.
14. Rybak SM, Pearson J, Fogler W, Volker K, Spence S, Newton D, Mikulski S, Ardelt W, Riggs C, Kung H and Longo D: Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with ONCONASE an antitumor ribonuclease. J Natl Cancer Inst 88: 747-753, 1996.
15. Deptala A, Halicka HD, Ardelt W, Mikulski SM, Shogen K and Darynkiewicz Z: Potentiation of tumor necrosis factor induced apoptosis by onconase. Int J Oncol 13: 11-16, 1998.
16. Mikulski S, Viera A, Ardelt W, Menduke H and Shogen K: Tamoxifen and trifluroperazine(Stelazine) potentiates cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing antitumor activity. Cell Tissue Kinet 32: 237-246, 1990.
17. Mikulski SM, Viera A, Deptala A and Darzynkiewicz Z: Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. Int J Oncol 13: 633-648, 1998.
18. KIP and decreased pRb phosphorylation. Leukemia 12: 1241-1248, 1998.
19. Lee I, Kim DH, Sunar U, Magnitsky S and Shogen K: The therapeutic mechanisms of ranpirnase-induced enhancement of radiation response on A549 human lung cancer. In Vivo 21:721-728, 2007.
20. Vasandani VM, Castelli JC, Hott JS, Saxena S, Mikulski SM and Youle RJ: Interferon enhances the activity of anticancer ribonuclease, Onconase. J Interferon & Cytokine Res 19: 447-454, 1999.
21. Halicka HR, Ardelt B, Shogen K and Darzynkiewicz Z: Mild hyperthermia predisposes tumor cells to undergo apoptosis upon treatment with onconase. Int J Oncl 30(4): 841-847, 2007.
22. Coffey DS, Getzenberd RH and Dee Weese TL: Hyperthermic biology and cancer therapies. A hypothesis of 'Lance Armstrong effect'. JAMA 296: 445-448, 2006.
23. Diallo M, Arenz C, Schmitz K, Sandhoff K and Schepers U: Long endogenous dsRNA can induce complete gene silencing in mammalian cells and primary cultures. Oligonucleotides 13: 381-392, 2003.
24. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811, 1998.
25. Misquitta L and Paterson BM: Targeted disruption of gene function in Drosophila by RNA interference (RNA-i): A role of nautilus in embryonic somatic muscle formation. Proc Natl Acad Sci 96: 1451-1456, 1999.
26. Tuschl T, Zamore PD, Lehmann R, Bartell DP and Sharp PA: Targeted mRNA degradation by double stranded RNA in vitro. Genes Dev 13: 3191-3197, 1999.
27. Jelinek W and Darnell JE: Double-stranded regions in heterogeneous nuclear RNA from HeLa cells. Proc Natl Acad Sci 69: 2537-2541, 1972.
28. Wang Q and Carmichael GG: Effects of length and location on the cellular response to double-stranded RNA. Microbiol Mol Biol Rev 68: 432-452, 2004.
29. Lee SB, Green SR, Mathews MB and Esteban M: Activation of double-stranded RNA(dsRNA)-activated human protein kinase in vivo in the absence of its dsRNA binding domain. Proc Natl Acad Sci 91: 10551-10555, 1994.
30. Lee SB, Rodriguez D, Rodriguez JR and Esteban M: The apoptosis pathway triggered by the interferon induced protein kinase PKR requires the third basic domain, initiates upstream of Bcl-2, and involves ice like proteases. Virology 231: 81-88, 1997.
31. Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K and Barber GN: Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J 17: 6888-6902, 1998.
32. Gil J, Garcia MA and Esteban M: Caspase 9 activation by the dsRNA-dependent protein kinase, PKR: molecular mechanism and relevance. FEBS Lett 529: 249-255, 2002.
33. Thanos D and Maniatis T: NF-kappa B: a lesson in family values. Cell 80: 529-532, 1995.
34. Cuddihy AR, Li S, Tam NW, Wong AH, Taya Y, Abraham N, Bell JC and Koromilas AE: Double stranded RNA activated protein kinase PKR enhances transcriptional activation by tumor suppressor p53. Mol Cell Biol 19: 2475-2484, 1999.
35. Gil J and Esteban M: Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action. Apoptosis 5: 107-114, 2000.
36. Yeung MC, Liu J and Lau AS: An essential role for the interferon-inducible, double-stranded RNA-activated protein kinase PKR in the tumor necrosis factor-induced apoptosis in U937 cells. Proc Natl Acad Sci 93: 12451-12455, 1996.
37. Gilbert SJ, Duance VC and Mason DJ: Tumor necrosis factor alpha up-regulates protein kinase R (PKR)-activating protein (PACT) and increases phosphorylation of PKR and eukaryotic initiation factor 2-alpha in articular chondrocytes. Biochem Soc Trans 30(6): 886-889, 2002.
38. Lee SB and Esteban M: The interferon induced double stranded RNA- activated protein kinase induces apoptosis. Virology 199: 491-496, 1994.
39. Hannon GJ: RNA interference. Nature 418: 244-251, 2002.
40. Herbst RS, Onn A and Sandler A: Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23: 3243-3256, 2005.
41. Zhang H, Kolb FA, Jaskiewicz L, Westhof E and Filipowicz W: Single processing center models for human dicer and bacterial RNAse III. Cell 118: 57-68, 2004.
42. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M and Croce CM: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005.
43. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC and Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci 103: 2257-2261, 2006.
44. Massimo L and Sorrentino S: Revisiting the action of bovine ribonuclease A and pancreatic-type ribonucleases on double stranded RNA. Mol and Cell Biochem 117: 139-151, 1992.